Hypertriglyceridemia - Pipeline Insight, 2025

DelveInsight’s, “Hypertriglyceridemia - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hypertriglyceridemia: Understanding

Hypertriglyceridemia: Overview

Hypertriglyceridemia is a medical condition characterized by elevated levels of triglycerides in the blood, often associated with an increased risk of cardiovascular disease (CVD) and acute pancreatitis. Common causes include uncontrolled diabetes, obesity, sedentary lifestyle, and genetic factors. While triglyceride levels typically remain asymptomatic until they exceed 1000-2000 mg/dL, severe elevations can lead to complications such as pancreatitis and metabolic disturbances. Management primarily involves lifestyle modifications such as dietary changes, weight loss, and increased physical activity alongside pharmacological treatments like statins or fibrates when necessary. Monitoring and addressing underlying conditions are crucial for effective management and prevention of associated risks.

Hypertriglyceridemia is usually asymptomatic but can present with various signs and symptoms, particularly at extremely high triglyceride levels. When triglycerides exceed 500 mg/dL, there is an increased risk of acute pancreatitis, which manifests with severe abdominal pain, nausea, and vomiting. In certain genetic forms, patients may develop xanthomas—small, yellowish skin lesions commonly found around the eyes, elbows, and knees. Other less common signs include hepatosplenomegaly (enlargement of the liver and spleen) and lipemia retinalis, a condition affecting the eyes. While hypertriglyceridemia itself may not cause noticeable symptoms, it serves as an indicator of underlying metabolic disorders and significantly raises the risk of cardiovascular diseases.

It occurs due to an imbalance between triglyceride production and clearance, leading to their accumulation in the blood. Impaired lipoprotein lipase (LPL) activity, genetic mutations, and regulatory protein dysfunction hinder triglyceride metabolism. Secondary factors like insulin resistance, obesity, diabetes, alcohol use, and certain medications further elevate triglyceride levels. Excess triglycerides contribute to pancreatitis, endothelial dysfunction, oxidative stress, and increased cardiovascular risk.

The diagnosis of hypertriglyceridemia is based on fasting serum triglyceride levels, with levels above 150 mg/dL considered elevated and those exceeding 500 mg/dL posing a high risk for complications like pancreatitis. Laboratory tests, including lipid panels, help assess triglyceride levels, while additional evaluations may identify underlying causes such as genetic disorders, diabetes, or metabolic syndrome. Treatment focuses on lifestyle modifications, including a low-fat, low-carbohydrate diet, regular exercise, weight management, and limiting alcohol intake. Pharmacologic interventions, such as fibrates, omega-3 fatty acids, niacin, and statins, are considered in cases of severe hypertriglyceridemia or when cardiovascular risk is high. In patients with extremely high triglycerides, immediate management aims to prevent pancreatitis through dietary fat restriction and, in some cases, plasmapheresis.

""Hypertriglyceridemia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypertriglyceridemia.

Hypertriglyceridemia Emerging Drugs Chapters

This segment of the Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypertriglyceridemia Emerging Drugs

SEFA-1024: NorthSea Therapeutics

SEFA-1024 is an oral, gut/liver targeted, semi-synthetic eicosapentaenoic acid derivative in development for the treatment of severe hypertriglyceridemia (sHTG). sHTG significantly increases the risk of acute pancreatitis a may increase cardiovascular event risk. There is a significant unmet medical need due to inadequate efficacy of existing therapies on TG, non-HDL-C, and glycemic control. Based on extensive pre-clinical data from a translatable model of human HTG, SEFA-1024 has the potential to address the unmet needs in treating sHTG. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Hypertriglyceridemia.

DR10624: Doer Biologics

DR10624 is a first-in-class long-acting tri-agonist targeting FGF21R, GLP-1R, and glucagon receptor (GCGR). Developed using Doer Bio’s proprietary MultipleBody platform technology, DR10624 was engineered to exhibit balanced activity for metabolic diseases. In non-clinical studies, DR10624 has demonstrated extraordinary potency in reducing body weight, lowering triglycerides, normalizing blood lipids, and improving liver function. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Severe Hypertriglyceridemia.

GC304: Genecradle Therapeutics

GC304 adeno-associated virus injection is a recombinant AAV viral vector carrying the LPL gene expression cassette. LPL is a key enzyme in the human body for hydrolyzing plasma-rich lipoprotein triglycerides. GC304 injection, through the efficient expression of the artificially optimized LPLS447X gene, a natural beneficial mutant of LPL, in the human body, can degrade triglycerides in circulating blood over the long term and efficiently, providing a new type of gene drug for the prevention and/or treatment of severe hypertriglyceridemia. Currently, the drug is in Phase I stage of its clinical trial for the treatment of hypertriglyceridemia.

Further product details are provided in the report……..

Hypertriglyceridemia: Therapeutic Assessment

This segment of the report provides insights about the different Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hypertriglyceridemia

There are approx. 18+ key companies which are developing the therapies for Hypertriglyceridemia. The companies which have their Hypertriglyceridemia drug candidates in the most advanced stage, i.e. Phase II include, NorthSea Therapeutics.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypertriglyceridemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertriglyceridemia drugs.

Hypertriglyceridemia Report Insights

Hypertriglyceridemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Hypertriglyceridemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Hypertriglyceridemia drugs?

How many Hypertriglyceridemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertriglyceridemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypertriglyceridemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hypertriglyceridemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

NST-1024

Plozasiran Injection

DR10624

Olezarsen

GC304

MN-001

mibavademab

Key Products

NorthSea Therapeutics

Arrowhead Pharmaceuticals

Zhejiang Doer Biologics

Ionis Pharmaceuticals, Inc.

GeneCradle

MediciNova

Regeneron Pharmaceuticals

Please Note: It will take 2-3 business days to complete the report upon order confirmation.